Rapid Analysis of Amphetamines in Biological Samples
The Application Notebook
This study demonstrates a faster method of analysis when coupling a simplified and effective SPE procedure with a core-shell HPLC column and LC–MS-MS detection.
This study demonstrates a faster method of analysis when coupling a simplified and effective SPE procedure with a core-shell HPLC column and LC–MS-MS detection.
Recently, the Substance Abuse and Mental Health Services Administration (SAMHSA) has lowered the amphetamine drug class cutoff level and has added MDMA, MDA, and MDEA to the panel. As a result, there will undoubtedly be an increase in positive result conformational testing, placing additional stress on the toxicology laboratory. We demonstrate how a specialized SPE sorbent and method, together with a high efficiency core-shell HPLC column and LC–MS-MS can decrease analysis time and increase sample throughput.
Experimental Conditions
Urine samples were pretreated and cleaned up using Strata™-X-Drug B solid phase extraction tubes. (It is important to note that neither a conditioning or equilibration step is required using this specialized SPE sorbent and method.) After diluting samples by a factor of 20 to bring the concentration into a suitable range for analysis, samples were injected onto the LC–MS-MS.
Analyses were performed using an HP 1100 LC system (Agilent Technologies, Palo Alto, California) with an upper pressure limit of 400 bar, equipped with an API 3000™ LC–MS-MS detector.
All analytes were present at a concentration of 10 ng/mL each and are listed in order of elution.
Column: Kinetex® 2.6 μm XB-C18 100 Å
Dimensions: 50 x 2.1 mm
Mobile Phase:
A: 5 mM Ammonium formate with 0.1 % Formic acid
Flow Rate: 0.4 mL/min
Detection: API 3000™ MS/MS, ESI negative (ESI-)
Sample: 1. D11-Amphetamine; 2. Amphetamine; 3. D14-Methamphetamine; 4. Methamphetamine; 5. D5-MDA; 6. MDA; 7. D5-MDMA; 8. MDMA; 9. D5-MDEA; 10. MDEA
Request a copy of Technical Note TN-1096 for complete method details.
Results
The Strata-X-Drug B SPE procedure consists of only 5 steps, a load, two washes, dry, and an elution step, compared to the 9 step procedure called for by the traditional SPE method. The new Strata-X-Drug B resulted in a 7 min time savings and 11 mL solvent savings.
Figure 1 demonstrates the ability of the Kinetex 2.6 μm XB-C18 columns to rapidly screen amphetamines while providing efficient conformational results. Complete analysis is completed in less than 3 min with an average peak width of 0.147.
Figure 1: Rapid analysis of amphetamines by LCâMS-MS using a Kinetex XB-C18 2.6 μm, 50 à 2.1 mm.
LC analysis was completed at operating pressures less than 400 bar and may therefore be used on any HPLC system without the need for specialized ultra-high pressure equipment.
Conclusion
A rapid cleanup and analysis for amphetamines was developed using Strata-X-Drug B SPE and a Kinetex XB-C18 HPLC column which can dramatically improve the efficiency of toxicology laboratories while simultaneously reducing cost due to solvent consumption. These time and solvent savings can be multiplied to provide substantial savings when running multiple samples in a high capacity laboratory.
Phenomenex, Inc.
411Madrid Avenue, Torrance, CA 90501
tel. (310) 212-0555, fax (310) 328-7768
Website: www.phenomenex.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
